sever
form
pneumonia
potenti
evolv
toward
acut
respiratori
distress
syndrom
ard
occasion
associ
multiorgan
failur
lead
complic
respiratori
viru
produc
outbreak
pandem
proport
coronaviru
diseas
recent
renam
solubl
cluster
differenti
cd
subtyp
amino
acid
kda
also
term
presepsin
psp
small
solubl
peptid
gener
solubl
known
function
regulatori
factor
modul
immun
respons
interact
b
cell
current
result
mani
clinic
studi
indic
psp
use
biomark
earli
diagnosi
also
risk
stratif
prognosi
predict
sepsi
patient
well
patient
suffer
pneumonia
order
verifi
potenti
use
biomark
risk
stratif
patient
n
suffer
microbiolog
proven
infect
tabl
psp
measur
lithiumheparin
plasma
sampl
use
chemiluminesc
enzym
immunoassay
cleia
pathfast
chemic
medienc
corpor
tokyo
japan
carri
addit
routin
laboratori
test
perform
period
hospit
januari
march
intens
care
unit
icu
n
andor
infecti
diseas
ward
iw
n
biochem
paramet
measur
use
coba
system
roch
diagnost
gmbh
mannheim
germani
except
procalcitonin
pct
liaison
brahm
pct
ii
gen
diasorin
spa
saluggia
itali
c
reactiv
protein
crp
dimens
vista
siemen
healthcar
diagnost
inc
tarrytown
usa
hematolog
data
obtain
use
sysmex
xe
sysmex
kobe
japan
ct
scan
perform
time
admiss
reveal
abnorm
result
patient
groundglass
opac
bilater
patchi
shadow
common
pattern
accord
sever
evolut
diseas
n
patient
admit
iw
move
day
icu
n
die
popul
studi
result
relev
routin
laboratori
test
may
provid
prognost
inform
suggest
studi
show
tabl
lymphocytopenia
lymphocyt
l
thrombocytopenia
platelet
l
http
receiv
april
receiv
revis
form
april
accept
april
patient
respect
increas
ddimer
crp
concentr
mgl
patient
respect
pct
valu
higher
observ
time
hospit
rang
day
median
day
comparison
biomark
carri
consid
result
avail
day
psp
measur
hospit
day
admiss
demonstr
statist
signific
higher
valu
mannwhitney
test
patient
die
median
iqr
vs
ngl
p
well
patient
stay
icu
time
hospit
median
iqr
vs
ngl
p
accord
roc
curv
analysi
auc
presepsin
valu
predict
mortal
p
furthermor
studi
relationship
spearman
correl
test
psp
differ
biochem
paramet
reflect
inflamm
evidenc
statist
signific
poor
correl
crp
r
p
ldh
r
p
stronger
pct
r
p
valu
despit
correl
pct
show
valu
higher
die
patient
patient
studi
behavior
blood
cell
coagul
test
prove
independ
psp
biochem
paramet
analyz
routin
popul
patient
interest
relev
inform
observ
studi
seem
associ
psp
concentr
hospit
patient
show
valu
higher
cutoff
suggest
manufactur
identifi
patient
high
risk
poor
outcom
ng
l
stay
icu
significantli
longer
time
median
day
iqr
exhibit
lower
valu
median
day
iqr
fig
logist
regress
analysi
support
find
ci
p
hospit
period
patient
show
higher
psp
concentr
addit
sensit
specif
propos
cutoff
relat
median
length
stay
observ
studi
day
respect
data
obtain
seem
demonstr
role
biomark
provid
prognost
inform
also
patient
alreadi
describ
sever
differ
diseas
allow
identifi
earli
phase
monitor
patient
suffer
sever
diseas
hospit
long
time
elev
psp
result
doserespons
mechan
hostpathogen
interact
occur
initi
phase
pathogen
recognit
remain
elev
sever
day
basi
diseas
sever
underlin
addit
valu
biomark
prognost
assess
patient
studi
present
limit
name
unavail
sampl
admiss
measur
psp
limit
number
die
patient
allow
reliabl
evalu
valu
psp
mortal
predict
addit
studi
need
better
explain
mechan
involv
psp
increas
patient
particular
relat
multiorgan
failur
syndrom
mof
